Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry. So far, the progress of uncovering single nucleotide polymorphisms (SNPs) underpinning treatment efficacy in mood disorders (e.g., SNPs associated with selective serotonin re-uptake inhibitors or lithium treatment response in patients with bipolar disorder and major depressive disorder) are encouraging, but not adequate. Genetic studies have pointed to a number of SNPs located at candidate genes that possibly influence response to; (a) antidepressants COMT,HTR2A,HTR1A,CNR1,SLC6A4, NPY,MAOA,IL1B,GRIK4,BDNF,GNB3,FKBP5,CYP2D6,CYP2C19, and ABCB1 and (b) mood stabilizers (lithium)5-HTT,TPH,DRD1,FYN,INPP1,CREB1,BDNF,GSK3β,ARNTL,TIM,DPB,NR3C1,BCR,XBP1, and CACNG2. We suggest three alternative and complementary strategies to implement knowledge gained from pharmacogenomic studies. The first strategy can be to implement diagnostic, therapeutic, or prognostic genetic testing based on candidate genes or gene products. The second alternative is an integrative analysis (systems genomics approach) to combine omics data obtained from the different pillars of omics investigation, including genomics, epigenomes, proteomics, metabolomics and microbiomes. The main goal of system genomics is an identification and understanding of biological pathways, networks, and modules underlying drug-response. The third strategy aims to the development of multivariable diagnostic or prognostic algorithms (tools) combining individual’s genomic information (polygenic score) with other predictors (e.g., omics pillars, neuroimaging, and clinical characteristics) to finally predict therapeutic outcomes. An integration of molecular science with that of traditional clinical practice is the way forward to drug discoveries and novel therapeutic approaches and to characterize psychiatric disorders leading to a better predictive, preventive, and personalized medicine (PPPM) in psychiatry. With future advances in the omics technology and methodological developments for data integration, the goal of PPPM in psychiatry is promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821 · cited 2×
“HTR2A 5-hydroxytryptamine receptor 2A Encodes one of the receptors for serotonin Polymorphisms in 5HT-2A receptor rs17288723 [72], rs7997012 [102, 103], rs9534505 [93], rs6311, rs6313, rs7997012, and rs1928040 [91, 102] were significantly associated with therapeutic response or remission to antidepressants [102]”
BackgroundMethodGenetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 2×
“BPD are highly heritable, and genetic factors contribute 31– 42% of the disease risk in MDD [109] and 59–85% in BPD [71, 77].”
BackgroundFerrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.12 · Cited by 2,627 · cited 1×
“prevalence of ~ 12 [4] and 1% [80], respectively.”
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) · Nature Genetics · doi:10.1038/ng.2711 · Cited by 2,263
Lichtenstein, P., Yip, B. H., Björk, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., & Hultman, C. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60072-6 · Cited by 2,125
Psychiatric GWAS Consortium Bipolar Disorder Working Group, Sklar, P., Ripke, S., Scott, L. J., Andreassen, O. A., Cichon, S., Craddock, N., Edenberg, H. J., Nurnberger, J. I., Rietschel, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.943 · Cited by 1,344
The Heritability of Bipolar Affective Disorder and the Genetic Relationship to Unipolar Depression
McGuffin, P., Rijsdijk, F., Andrew, M., Sham, P., Katz, R., & Cardno, A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.497 · Cited by 1,243
Methods of integrating data to uncover genotype-phenotype interactions
Ritchie, M. D., Holzinger, E. R., Li, R., Pendergrass, S. A., & Kim, D. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3868 · Cited by 1,085
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 8×
“Individual clinical trials currently part of the Novel Methods Leading to New Medications in Depression and Schizophrenia (NEWMEDS) consortium (http://www.newmeds-europe.com) include three studies from academic institutions (GENDEP, n = 868; GENPOD, n = 601; and Geneva Outpatient Depression Study (GODS), n = 131) and…”
MethodInfluentialAndrade, L., Caraveo‐anduaga, J. J., Berglund, P., Bijl, R. V., Graaf, R. D., Vollebergh, W., Dragomirecka, E., Kohn, R., Keller, M., Kessler, R. C., et al. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.138 · Cited by 1,068 · cited 1×
“prevalence of ~ 12 [4] and 1% [80], respectively.”
Sparse whole-genome sequencing identifies two loci for major depressive disorder
CONVERGE consortium, Cai, N., Bigdeli, T. B., Kretzschmar, W., Li, Y., Liang, J., Song, L., Hu, J., Li, Q., Jin, W., et al. (2015) · Nature · doi:10.1038/nature14659 · Cited by 864
Hyde, C. L., Nagle, M. W., Tian, C., Chen, X., Paciga, S. A., Wendland, J. R., Tung, J. Y., Hinds, D. A., Perlis, R. H., & Winslow, A. R. (2016) · Nature Genetics · doi:10.1038/ng.3623 · Cited by 784 · cited 4×
“Candidate gene and genome-wide association studies (GWASs) have identified a list of candidate genes for MDD [20, 24, 35, 59] and BPD [55, 84, 92, 106].”
BackgroundMethodInfluentialThe Genetics of Major Depression
Flint, J., & Kendler, K. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.027 · Cited by 724 · cited 1×
“Candidate gene and genome-wide association studies (GWASs) have identified a list of candidate genes for MDD [20, 24, 35, 59] and BPD [55, 84, 92, 106].”
BackgroundCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676
Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661
Systems genetics approaches to understand complex traits
Civelek, M., & Lusis, A. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3575 · Cited by 621
The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013
Ferrari, A. J., Stockings, E., Khoo, J., Erskine, H. E., Degenhardt, L., Vos, T., & Whiteford, H. A. (2016) · Bipolar Disorders · doi:10.1111/bdi.12423 · Cited by 583
Is Response to Prophylactic Lithium a Familial Trait?
Grof, P., Duffy, A., Cavazzoni, P., Grof, E., Garnham, J., MacDougall, M., O'Donovan, C., & Alda, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1013 · Cited by 438 · cited 1×
“While clinical studies report a combination of demographic and clinical characteristics as potential predictors of treatment response in mood disorder patients [66], genetic factors are also highly involved in lithium treatment response with a potential interplay between genetic and environmental factors [47, 56].”
BackgroundMedicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016
Golubnitschaja, O., Baban, B., Boniolo, G., Wang, W., Bubnov, R., Kapalla, M., Krapfenbauer, K., Mozaffari, M. S., & Costigliola, V. (2016) · EPMA Journal · doi:10.1186/s13167-016-0072-4 · Cited by 396
Genome-wide association study reveals two new risk loci for bipolar disorder
Mühleisen, T. W., Leber, M., Schulze, T. G., Strohmaier, J., Degenhardt, F., Treutlein, J., Mattheisen, M., Forstner, A. J., Schumacher, J., Breuer, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4339 · Cited by 346
Epigenetic Mechanisms of Depression and Antidepressant Action
Vialou, V., Feng, J., Robison, A. J., & Nestler, E. J. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134540 · Cited by 277
Doherty, J. L., & Owen, M. J. (2014) · Genome Medicine · doi:10.1186/gm546 · Cited by 228 · cited 2×
“Moreover, patients with MDD and BPD often show overlapping clinical features [25].”
BackgroundEpigenetic alterations in depression and antidepressant treatment
Menke, A., & Binder, E. B. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/amenke · Cited by 161
The implications of the shared genetics of psychiatric disorders
O'Donovan, M. C., & Owen, M. J. (2016) · Nature Medicine · doi:10.1038/nm.4196 · Cited by 157 · cited 1×
“An extension of the GWAS approaches such as polygenic score analysis [87], bivariate restrictedmaximum likelihood (REML) in genome-wide complex trait analysis (GCTA) [21] and linkage disequilibrium (LD) score regression have strongly suggested that mood disorders are polygenic in nature, in that multiple genetic varia…”
MethodBiernacka, J. M., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V, Brockmöller, J., Chen, C. H., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.47 · Cited by 140 · cited 9×
“This enzyme might be involved in the metabolism of drugs [121] The Val (108/158) Met variation of the COMT gene is among the most studied polymorphisms associated with response to antidepressants treatment [10, 13, 151] or electroconvulsive therapy [42] in patients with MDD”
BackgroundMethodInfluentialSelf-citationPharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84 · cited 5×
“Cytochrome P450 family 2 subfamily D member 6 It is a highly polymorphic gene that encodes an enzyme in the CYPsuperfamily [121] Polymorphisms in the CYP2D6 gene may influence the metabolism and response of antidepressant response [16, 67, 90].”
BackgroundInfluential
Cited by
Pharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders
Bhattacharya, A., & Jones, D. N. C. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.08.015 · Cited by 105
Zelada, M. I., Garrido, V., Liberona, A., Jones, N., Zúñiga, K., Silva, H., & Nieto, R. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914810 · Cited by 60
Zhou, J., Li, M., Wang, X., He, Y., Xia, Y., Sweeney, J. A., Kopp, R. F., Liu, C., & Chen, C. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674273 · Cited by 56
Metadata
- Authors
- Amare, A. T., Schubert, K. O., & Baune, B. T.
- Venue
- EPMA Journal
- Published
- 2017-09
- Volume
- 8
- Issue
- 3
- Pages
- 211-227
- ISSN
- 1878-5077 (ISSN-L)
- 1878-5085
- OpenAlex
- W2751700789
- Cited by
- 129
- References
- 30
- FWCI
- 18.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.